tiprankstipranks
Trending News
More News >
Next Science Ltd (AU:NXS)
:NXS

Next Science Ltd (NXS) AI Stock Analysis

Compare
7 Followers

Top Page

AU

Next Science Ltd

(OTC:NXS)

Rating:37Underperform
Price Target:
AU$0.00
▼(-100.00%Downside)
The overall stock score of 37 is primarily driven by the company's challenging financial performance, marked by ongoing losses and negative cash flows. Technical analysis further supports a bearish outlook with the stock in oversold territory. Valuation concerns, including a negative P/E ratio, also weigh heavily on the stock's attractiveness, while the absence of dividends limits investor appeal.

Next Science Ltd (NXS) vs. iShares MSCI Australia ETF (EWA)

Next Science Ltd Business Overview & Revenue Model

Company DescriptionNext Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.
How the Company Makes MoneyNext Science Ltd generates revenue through the sale of its proprietary medical products aimed at treating biofilm-related infections. The company's key revenue streams include direct sales to healthcare providers, hospitals, and clinics, as well as partnerships with distributors and medical device companies. Additionally, Next Science may engage in licensing agreements to allow other companies to use its patented XBIO technology, further contributing to its earnings. Strategic partnerships and collaborations with healthcare organizations and research institutions also play a significant role in expanding its market reach and enhancing revenue opportunities.

Next Science Ltd Earnings Call Summary

Earnings Call Date:Feb 27, 2025
(Q2-2024)
|
% Change Since: -33.33%|
Next Earnings Date:Aug 27, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with significant growth in the Surgical business and improved gross margins, but these were offset by declines in DME and BLASTX sales due to sales force restructuring. The company remains optimistic by reaffirming revenue guidance and implementing strategic changes. However, the establishment of a loan facility indicates caution. Overall, the sentiment leans towards optimism but with notable areas of concern.
Q2-2024 Updates
Positive Updates
Surgical Business Growth
Direct sales of XPERIENCE increased by 72% over the prior period and 25% over the first quarter of 2024.
Improved Gross Margin
The company's gross margin increased to 80% in Q2, up from 69% in the second quarter of 2023, reflecting a continued focus on revenue quality.
Cash Position and Cost Management
Cash receipts for the quarter were USD 6 million, up 11% compared to Q1 2024. Net operating cash outflows decreased to USD 1.3 million from USD 3.7 million in the previous quarter.
Expansion of Payers
Next Science onboarded over 120 payers for the DME business, including private and government payers such as Medicare and Medicaid.
FY '24 Revenue Guidance Reaffirmed
The company reaffirmed its FY '24 revenue guidance of USD 36 million to USD 40 million and expects to be EBITDA and cash flow positive in the second half of FY '24.
Negative Updates
Decline in DME Sales
DME sales were down by 22% over the prior period, attributed to sales force restructuring disruptions.
BLASTX Direct Sales Decline
Direct sales of BLASTX fell by 6% over the same time period, also impacted by the sales restructure.
Need for Loan Facility
A USD 5 million unsecured loan facility was established with Thorney Investment Group as a precautionary measure, indicating potential financial uncertainty.
Company Guidance
During the Q2 2024 earnings call for Next Science, the management team provided guidance, projecting FY '24 revenue between USD 36 million to USD 40 million, and reaffirmed expectations to achieve EBITDA and cash flow positivity in the second half of the fiscal year. The company reported Q2 product sales of USD 5.8 million, marking a 5% increase over the prior period, with direct channel product sales contributing USD 4.4 million, accounting for 76% of the total. Despite a 22% decline in DME sales and a 6% drop in BLASTX direct sales due to a sales force restructuring, the Surgical business saw a 72% increase in direct sales of XPERIENCE. The quarter ended with a gross margin of 80%, surpassing the previous year's 69%, supported by an increase in payers to over 120. Cash receipts rose by 11% from Q1 to USD 6 million, with net operating cash outflows reduced to USD 1.3 million. The company aims to leverage the growing body of clinical evidence and broader healthcare site access to drive future growth.

Next Science Ltd Financial Statement Overview

Summary
Next Science Ltd faces significant financial challenges, with persistent losses and negative cash flows. Despite modest revenue growth, profitability is severely impacted by negative EBIT and EBITDA margins, and a deeply negative return on equity, indicating financial instability.
Income Statement
40
Negative
Next Science Ltd has experienced growth in revenue from 2023 to 2024, with a revenue growth rate of 2.87%. However, the company is facing significant challenges in profitability as indicated by negative EBIT and EBITDA margins. The net profit margin remains negative, highlighting ongoing losses and indicating the company is struggling to cover its operational costs.
Balance Sheet
30
Negative
The balance sheet reveals a strained financial position with a debt-to-equity ratio of 0.72, suggesting moderate leverage but reduced equity base. The return on equity is deeply negative at -307.61%, reflecting substantial losses relative to shareholder equity. The equity ratio stands at 37.37%, indicating a relatively balanced capital structure but a decline from previous years.
Cash Flow
35
Negative
Next Science Ltd's cash flow indicates operational challenges with negative operating and free cash flows. The free cash flow to net income ratio is negative, showing cash outflows persist. There is no positive cash flow growth, implying potential liquidity issues and limited cash generation capability.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
22.82M22.18M16.90M
Gross Profit
18.44M16.23M11.90M
EBIT
-10.30M-15.95M-18.31M-9.28M-13.96M
EBITDA
-9.03M-14.42M-17.02M-13.18M
Net Income Common Stockholders
-10.59M-24.51M-18.30M-13.27M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.67M9.28M7.54M15.24M
Total Assets
9.21M17.90M18.37M13.67M23.49M
Total Debt
2.49M961.97K1.80M
Net Debt
819.25K-8.28M-5.68M
Total Liabilities
5.77M5.08M6.52M
Stockholders Equity
3.44M12.82M11.85M10.73M18.80M
Cash FlowFree Cash Flow
-8.55M-15.94M-17.69M-14.03M
Operating Cash Flow
-7.96M-15.06M-17.01M-13.26M
Investing Cash Flow
-589.22K-884.50K-686.23K
Financing Cash Flow
1.75M20.11M14.78M11.93M

Next Science Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.07
Price Trends
50DMA
0.09
Negative
100DMA
0.10
Negative
200DMA
0.13
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
27.91
Positive
STOCH
20.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NXS, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 27.91 is Positive, neither overbought nor oversold. The STOCH value of 20.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NXS.

Next Science Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUVIT
61
Neutral
AU$45.70M20.294.85%5.76%-79.76%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
AUAGH
45
Neutral
AU$21.39M-218.38%-14.30%29.69%
AUIDT
44
Neutral
AU$41.35M-19.31%72.25%43.66%
AUMVP
44
Neutral
AU$69.85M-45.40%13.61%-55.12%
AUNXS
37
Underperform
AU$19.87M-130.18%3.37%47.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:NXS
Next Science Ltd
0.07
-0.20
-74.34%
AU:MVP
Medical Developments International Limited
0.62
0.22
55.00%
AU:AGH
Althea Group Holdings Ltd.
0.03
<0.01
50.00%
AU:IDT
IDT Australia Limited
0.10
-0.02
-16.67%
AU:VIT
Cronos Australia Ltd.
0.07
-0.03
-30.00%

Next Science Ltd Corporate Events

Next Science Limited Announces Successful 2025 AGM Results
May 9, 2025

Next Science Limited announced that all resolutions were passed at its 2025 Annual General Meeting, as determined by a poll. This successful meeting outcome reflects positively on the company’s governance and may reinforce stakeholder confidence, potentially impacting its market positioning favorably.

Next Science Reports Operational Milestones and Strategic Growth in 2024
May 9, 2025

Next Science Limited held its 2025 Annual General Meeting, where the Chair and CEO highlighted significant operational improvements and strategic advancements made in 2024. The company reduced its cash burn by US$7 million, improved margins, and achieved cash flow positivity for two non-consecutive months. With a US$5 million loan facility secured, Next Science is well-positioned for future growth. Clinical research published in 2024 demonstrated the effectiveness of its products, BLASTX and XPERIENCE, in reducing infections and inflammation, contributing to lower healthcare costs. The company also continued its large-scale study on periprosthetic joint infections, enrolling 1,220 patients by the end of 2024. Despite a decline in the Durable Medical Equipment channel, Next Science achieved record revenue of US$22.8 million, driven by strong direct and partner sales.

Next Science’s Derivative Complaint Dismissed Amid Ongoing Litigation
May 4, 2025

Next Science Limited announced that a derivative complaint filed by Michael Morello in Florida’s Duval County Court has been dismissed due to lack of standing. However, the litigation initiated by Next Science LLC against Mr. Morello and other former employees for breach of post-employment restraints is still ongoing, indicating continued legal proceedings that may impact the company’s operations and stakeholder interests.

Next Science Ltd Announces Cessation of Securities
May 2, 2025

Next Science Ltd announced the cessation of 250,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perceptions, although the specific implications for stakeholders were not detailed in the release.

Next Science Reports Q1 FY25 Sales Decline Amid FDA Compliance Efforts
Apr 23, 2025

Next Science Limited reported a slight decline in product sales for the first quarter of FY25, with total sales of US$5.3 million, a 3% decrease from the prior corresponding period. Despite a significant increase in direct sales of XPERIENCE and BLASTX products, the overall sales were impacted by a decline in Durable Medical Equipment (DME) sales. The company maintained a strong gross margin of 84%, attributed to a favorable product mix. Additionally, Next Science addressed an FDA Warning Letter, ensuring that their products remain safe and effective for their intended uses, and continued to focus on achieving a positive cash flow position.

Next Science Limited Updates Corporate Governance Statement
Apr 17, 2025

Next Science Limited has released its updated corporate governance statement, which is now available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, reflecting its commitment to transparency and accountability. This move is expected to reinforce stakeholder confidence and align with industry standards, potentially impacting the company’s market perception positively.

Next Science Ltd Unveils 2024 Annual Report: A Year of Change, a Future of Growth
Apr 17, 2025

Next Science Ltd, a company known for its innovative solutions in the medical technology industry, has released its 2024 Annual Report titled ‘A Year of Change, a Future of Growth.’ The report highlights significant developments and strategic shifts aimed at fostering growth and enhancing market positioning. The company’s focus on its XBIO® portfolio and recent studies underscores its commitment to advancing medical technology solutions. This announcement is likely to have implications for stakeholders as it signals a proactive approach towards future growth and operational enhancement.

Next Science to Announce 1Q FY25 Results and Host Investor Webinar
Apr 10, 2025

Next Science Limited will release its first-quarter financial results for FY25 on April 24, 2025, followed by an investor webinar hosted by CEO I.V. Hall and CFO Marc Zimmerman. This announcement is part of the company’s ongoing efforts to engage with the investment community and provide transparency about its financial performance. The results and subsequent discussion could impact stakeholders’ perceptions and the company’s market positioning, particularly given its focus on innovative medical technology solutions.

Next Science Announces 2025 Annual General Meeting Details
Apr 4, 2025

Next Science Limited has announced that its 2025 Annual General Meeting (AGM) will take place on May 9, 2025, at 10:00 am Sydney time. The AGM will be a hybrid event, allowing shareholders to attend either in person at the company’s Share Registrar office in Sydney or virtually via the Zoom platform. This meeting provides an opportunity for shareholders to engage with the company, ask questions, and participate in voting, reflecting Next Science’s commitment to transparent communication and stakeholder engagement.

Next Science Announces Change in Share Registry Provider
Mar 13, 2025

Next Science Limited has announced a change in its securityholder registry services provider from MUFG Corporate Markets (AU) Limited to Automic Pty Ltd, effective from March 17, 2025. This change allows shareholders to manage their holdings through Automic’s secure online investor portal, enhancing the efficiency and accessibility of shareholder services. This strategic move is expected to streamline operations and improve stakeholder engagement.

Next Science Schedules 2025 Annual General Meeting
Mar 11, 2025

Next Science Limited has announced that its 2025 Annual General Meeting will take place on Friday, 9 May 2025, at 10:00 am Sydney time. The company has set 19 March 2025 as the deadline for director nomination submissions. This announcement is part of the company’s ongoing efforts to engage with stakeholders and ensure transparent governance practices.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.